SCHEMBL21381950

SCHEMBL21381950

O=C(ON1CCC(c2ccc(OC(F)(F)F)cc2)C1)C(F)(F)F

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 1/20 0.45
KMT2A Q03164 1/20 0.45
EPHX2 P34913 9/20 0.43
FAAH O00519 1/20 0.43
EPHX1 P07099 1/20 0.41
HRH3 Q9Y5N1 1/20 0.39
HSD11B1 P28845 1/20 0.39
F2R P25116 2/20 0.39
CNR1 P21554 1/20 0.39
TMEM97 Q5BJF2 1/20 0.39
GRM2 Q14416 1/20 0.39
KDM2B Q8NHM5 1/20 0.39
MGLL Q99685 1/20 0.39
LIPE Q05469 1/20 0.38
CYP2C9 P11712 1/20 0.38
CYP2C19 P33261 1/20 0.38
DRD2 P14416 1/20 0.38
DRD1 P21728 1/20 0.38
DRD4 P21917 1/20 0.38
DRD5 P21918 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL942295 0.92 EPHX2 (0.47) MEN1KMT2AEPHX2FAAHEPHX1
SCHEMBL21381996 0.85 NOTUM (0.47) MEN1KMT2AFAAHHSD11B1MGLL
SCHEMBL22638731 0.84 HTR2C (0.42) F2RLIPE
SCHEMBL15571861 0.84 MAPT (0.43) CYP2C9CYP2C19DRD2DRD1DRD4
SCHEMBL28752729 0.82 EPHX2 (0.46) MEN1KMT2AEPHX2FAAHEPHX1
SCHEMBL23212064 0.78 MEN1 (0.52) MEN1KMT2AEPHX2FAAHEPHX1
SCHEMBL28279289 0.78 LIPE (0.32) LIPEDRD2DRD1DRD4DRD5
SCHEMBL381670 0.76 MMP3 (0.50) HRH3HSD11B1DRD2
SCHEMBL23211941 0.76 GPR119 (0.56) MEN1KMT2AEPHX2FAAHLIPE
SCHEMBL6113980 0.76 F2R (0.66) MEN1KMT2AEPHX2HRH3F2R

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-111936503-B Oxazine monoacylglycerol lipase (MAGL) inhibitors 豪夫迈·罗氏有限公司 2023-09-12 CN disclosed
US-20230117324-A1 OXAZINE MONOACYLGLYCEROL LIPASE (MAGL) INHIBITORS HOFFMANN-LA ROCHE INC. (US) 2023-04-20 US disclosed
EP-3768684-B1 OXAZINE MONOACYLGLYCEROL LIPASE (MAGL) INHIBITORS HOFFMANN LA ROCHE (CH) 2023-02-22 EP disclosed
US-20210107920-A1 OXAZINE MONOACYLGLYCEROL LIPASE (MAGL) INHIBITORS HOFFMANN-LA ROCHE INC. (US) 2021-04-15 US disclosed
EP-3768684-A1 OXAZINE MONOACYLGLYCEROL LIPASE (MAGL) INHIBITORS F. Hoffmann-La Roche AG (CH) 2021-01-27 EP disclosed
CN-111936503-A Oxazin monoacylglycerol lipase (MAGL) inhibitors 豪夫迈·罗氏有限公司 2020-11-13 CN disclosed
WO-2019180185-A1 OXAZINE MONOACYLGLYCEROL LIPASE (MAGL) INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2019-09-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210107920-A1 OXAZINE MONOACYLGLYCEROL LIPASE (MAGL) INHIBITORS MGLL, LPL, LIPC MEN1 1218/4885KMT2A 2681/4885EPHX2 402/4885
US-20230117324-A1 OXAZINE MONOACYLGLYCEROL LIPASE (MAGL) INHIBITORS MGLL, LPL, LIPC MEN1 1218/4885KMT2A 2681/4885EPHX2 402/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.